Czech National Bank Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Czech National Bank lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 270,216 shares of the biopharmaceutical company’s stock after acquiring an additional 16,598 shares during the period. Czech National Bank’s holdings in Gilead Sciences were worth $24,960,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at about $25,000. Valued Wealth Advisors LLC grew its stake in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Cedar Wealth Management LLC increased its holdings in Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 160 shares during the period. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the 2nd quarter worth approximately $33,000. Finally, Quarry LP bought a new position in Gilead Sciences in the 2nd quarter valued at $43,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of several research analyst reports. Wolfe Research initiated coverage on shares of Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target on the stock. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. BMO Capital Markets boosted their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, Robert W. Baird raised their target price on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $97.96.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 8,500 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total value of $781,660.00. Following the transaction, the chief financial officer now owns 132,373 shares in the company, valued at $12,173,021.08. This trade represents a 6.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 453,734 shares of company stock valued at $41,902,086 in the last 90 days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $89.88 on Monday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The firm has a market cap of $112.01 billion, a PE ratio of 998.67, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The business has a 50 day moving average price of $91.94 and a 200-day moving average price of $83.39.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.29 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.43%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.